Edwards Lifesciences price target raised to $90 from $75 at Stifel After Edwards reported higher than expected Q1 EPS, Stifel thinks the company is doing well so far in 2014. The firm expects analysts' estimates to rise gradually over time as a result of several positive catalysts. It keeps a Buy rating on the shares.
Edwards Lifesciences price target raised to $120 from $95 at Piper Jaffray Piper Jaffray raised its price target for Edwards Lifesciences shares to $120 saying recent Transcatheter Aortic Valve Replacement market momentum is likely to continue. The firm keeps an Overweight rating on the stock.
Edwards Lifesciences price target raised to $114 from $103 at Canaccord Canaccord raised its price target on Edwards Lifesciences to $114 from $103 following positive updates on the SAPIEM franchise and on the heels of several positive trends and upside surprises across the businesses during the quarter. Canaccord maintains its Buy rating on the stock.